Discovery of a new mexiletine-derived agonist of the hERG K + channel

Gualdani, Roberta;Cavalluzzi, Maria Maddalena;Tadini-Buoninsegni, Francesco;Lentini, Giovanni
(2017) Biophysical Chemistry — Vol. 229, n° 229, p. 62-67 (2017)

Files

No attached file found for this publication.

Details

Authors
  • Author
  • Cavalluzzi, Maria Maddalena
    Author
  • Tadini-Buoninsegni, Francesco
    Author
  • Lentini, Giovanni
    Author
Abstract
The human Ether-a-go-go Related Gene (hERG) potassium channel plays a central role in the rapid component (IKr) of cardiac action potential repolarization phase. A large number of structurally different compounds block hERG and cause a high risk of arrhythmias. Among the drugs that block hERG channel, a few compounds have been identified as hERG channel activators. Such compounds may be useful, at least in theory, for the treatment of long term QT syndrome. Here we describe a new activator of hERG channel, named MC450. This compound is a symmetric urea, derived from (R)-mexiletine. Using patch-clamp recordings, we found that MC450 increased the activation current of hERG channel, with an EC50 of 41 ± 4 μM. Moreover MC450 caused a depolarizing shift in the voltage dependence of inactivation from − 64.1 ± 1.2 mV (control), to − 35.9 ± 1.4 mV, whereas it had no effect on the voltage dependence of activation. Furthermore, MC450 slowed current inactivation and the effect of MC450 was attenuated by the inactivation-impaired double mutant G628C/S631C.
Affiliations

Citations

Gualdani, R., Cavalluzzi, M. M., Tadini-Buoninsegni, F., & Lentini, G. (2017). Discovery of a new mexiletine-derived agonist of the hERG K + channel. Biophysical Chemistry, 229(229), 62-67. https://doi.org/10.1016/j.bpc.2017.06.005 (Original work published 2017)